Actively Recruiting
A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
Led by Janssen-Cilag Ltd. · Updated on 2026-05-08
200
Participants Needed
1
Research Sites
81 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the effectiveness and safety of guselkumab following a switch from ustekinumab or an ustekinumab biosimilar in participants with moderate to severe psoriasis, a chronic inflammatory skin disease characterized by erythematous, scaly plaques that may be associated with pain and pruritus, in routine clinical practice.
CONDITIONS
Official Title
A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment
- Currently treated with ustekinumab (originator or biosimilar) and medically indicated to switch to guselkumab
- Investigator has decided to start treatment with guselkumab
- Able and willing to answer patient-reported outcomes (PROs)
- Signed informed consent form for data collection and verification
You will not qualify if you...
- Contraindication or hypersensitivity to guselkumab or any ingredient in its injection solution
- Pregnancy or breastfeeding
- Currently enrolled in an interventional study
- Currently enrolled in an observational study sponsored or managed by a Janssen company
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
LKH-Univ. Klinikum Graz
Graz, Austria, 8036
Actively Recruiting
Research Team
S
Study Contact
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here